217 related articles for article (PubMed ID: 29658364)
1. Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: A systematic review and meta-analysis.
Zhang D; Liu Z; Yin X; Qi X; Lu B; Liu Y; Hou J
Int J Biol Markers; 2018 Aug; 33(3):266-274. PubMed ID: 29658364
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data.
Yu R; Tan Z; Xiang X; Dan Y; Deng G
BMC Cancer; 2017 Sep; 17(1):608. PubMed ID: 28863782
[TBL] [Abstract][Full Text] [Related]
3. Elevated PIVKA-II is associated with early recurrence and poor prognosis in BCLC 0-A hepatocellular carcinomas.
Wang BL; Tan QW; Gao XH; Wu J; Guo W
Asian Pac J Cancer Prev; 2014; 15(16):6673-8. PubMed ID: 25169507
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma.
Park H; Park JY
Biomed Res Int; 2013; 2013():310427. PubMed ID: 24455683
[TBL] [Abstract][Full Text] [Related]
5. PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study.
Svobodova S; Karlikova M; Topolcan O; Pecen L; Pestova M; Kott O; Treska V; Slouka D; Kucera R
In Vivo; 2018; 32(6):1551-1554. PubMed ID: 30348715
[TBL] [Abstract][Full Text] [Related]
6. NX-PVKA levels before and after hepatectomy of hepatocellular carcinoma as predictors of patient survival: a preliminary evaluation of an improved assay for PIVKA-II.
Nanashima A; Abo T; Taura N; Shibata H; Ichikawa T; Takagi K; Arai J; Oyama S; Nagayasu T
Anticancer Res; 2013 Jun; 33(6):2689-97. PubMed ID: 23749928
[TBL] [Abstract][Full Text] [Related]
7. PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy.
Takahashi S; Kudo M; Chung H; Inoue T; Ishikawa E; Kitai S; Tatsumi C; Ueda T; Nagai T; Minami Y; Ueshima K
Oncology; 2008; 75 Suppl 1():91-8. PubMed ID: 19092277
[TBL] [Abstract][Full Text] [Related]
8. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
[TBL] [Abstract][Full Text] [Related]
9. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
[TBL] [Abstract][Full Text] [Related]
10. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.
Kamiyama T; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamachi H; Yamashita K; Shimamura T; Taketomi A
World J Surg Oncol; 2017 Aug; 15(1):156. PubMed ID: 28830473
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
12. Development and evaluation of analytical performance of a fully automated chemiluminescent immunoassay for protein induced by vitamin K absence or antagonist II.
Fujita K; Kinukawa H; Ohno K; Ito Y; Saegusa H; Yoshimura T
Clin Biochem; 2015 Dec; 48(18):1330-6. PubMed ID: 26210849
[TBL] [Abstract][Full Text] [Related]
13. Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma.
Hong YM; Cho M; Yoon KT; Chu CW; Yang KH; Park YM; Rhu JH
Tumour Biol; 2017 Oct; 39(10):1010428317720863. PubMed ID: 29034775
[TBL] [Abstract][Full Text] [Related]
14. Protein induced by vitamin K antagonist-II (PIVKA-II) is a reliable prognostic factor in small hepatocellular carcinoma.
Kim JM; Hyuck C; Kwon D; Joh JW; Lee JH; Paik SW; Park CK
World J Surg; 2013 Jun; 37(6):1371-8. PubMed ID: 23443153
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.
Kang SH; Kim DY; Jeon SM; Ahn SH; Park JY; Kim SU; Kim JK; Lee KS; Chon CY; Han KH
Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):849-56. PubMed ID: 22495400
[TBL] [Abstract][Full Text] [Related]
16. Des-gamma-carboxy prothrombin in hepatocellular cancer patients waiting for liver transplant: a systematic review and meta-analysis.
Lai Q; Iesari S; Levi Sandri GB; Lerut J
Int J Biol Markers; 2017 Oct; 32(4):e370-e374. PubMed ID: 28561879
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of PIVKA-II After Living-donor Liver Transplantation for Hepatocellular Carcinoma.
Park MS; Lee KW; Kim H; Choi YR; Hong G; Yi NJ; Suh KS
Transplant Proc; 2017 Jun; 49(5):1109-1113. PubMed ID: 28583537
[TBL] [Abstract][Full Text] [Related]
18. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
Lee S; Rhim H; Kim YS; Kang TW; Song KD
Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
[TBL] [Abstract][Full Text] [Related]
19. Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma.
Nanashima A; Morino S; Yamaguchi H; Tanaka K; Shibasaki S; Tsuji T; Hidaka S; Sawai T; Yasutake T; Nakagoe T
Eur J Surg Oncol; 2003 Nov; 29(9):735-42. PubMed ID: 14602492
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]